PMA device
XACT® Carotid Stent System
Abbott Vascular, Inc. · Stent, Carotid (NIM, Class III) · First FDA decision Sep 6, 2005, newest Dec 9, 2025Carotid artery disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
13
PMA pathway
Device trials
10
Naming "XACT"
MAUDE reports
267
Brand "XACT", since 2015
PubMed studies
165
Mentioning "XACT"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing XACT® Carotid Stent System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 13 decisions filed under this name.
- XACT® Carotid Stent SystemPMA supplement
P040038-S048 · Decided Dec 9, 2025 · 211 days after receipt · Normal 180 Day Track No User Fee
Device type: Stent, carotid (NIM) · Cardiology
5 more FDA decisions with a free account
Older decisions: P040038-S019, P040038-S018, P040038-S015, P040038-S012, P040038-S007, P040038-S001, P040038
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R8Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R7Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R6Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R3Updated Sep 21, 2026
- Carotid Artery Stenting in Post-Approval StudiesNational analysisReview closedCAG-00259NUpdated Sep 17, 2026
- Carotid Artery StentingNational analysisReview closedCAG-00085RUpdated Sep 17, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "XACT", any status and sponsor, newest update first.
- XACT ACE Observational RegistryStatus unknown
Xact Robotics Ltd.Not on our public-company list
NCT04950959 · 500 participants (planned) · Start Oct 1, 2021 · Primary completion Jul 1, 2026
Device: Hands-free, user-controlled robotic system intended to assist in the planning and advancement of an instrument during CT guided percutaneous procedures. T · For: Tumors
Sites: Burlington, Massachusetts
9 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "XACT", and for the whole product code for context.
This brand
267 reports: 110 malfunction, 143 injury, 14 death
Whole product code NIM
2,799 reports: 1,699 malfunction, 994 injury, 98 death
Newest reports for this brand
- XACTInjury
2024168-2026-03576 · Received Sep 16, 2026 · Event dated May 15, 2012
Device type: Stent, Carotid (NIM)
Device problem as coded: Break
Patient problem as coded: Obstruction/Occlusion
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "XACT"[tiab]. The summary above synthesizes these.
- [Capecitabine].
Yamaguchi K, Shimamura T, Tada M · Gan To Kagaku Ryoho · 2006English Abstract, Review
- X-ray induced acoustic computed tomography.
Samant P, Trevisi L, Ji X, et al. · Photoacoustics · 2020Review
- The feasibility study of XACT imaging for characterizing osteoporosis.
Li Y, Samant P, Cochran C, et al. · Med Phys · 2022
- XIST dampens X chromosome activity in a SPEN-dependent manner during early human development.
Alfeghaly C, Castel G, Cazottes E, et al. · Nat Struct Mol Biol · 2024Research Support, Non-U.S. Gov't
- XACT-Seq Comprehensively Defines the Promoter-Position and Promoter-Sequence Determinants for Initial-Transcription Pausing.
Winkelman JT, Pukhrambam C, Vvedenskaya IO, et al. · Mol Cell · 2020Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Deletion of lncRNA XACT does not change expression dosage of X-linked genes, but affects differentiation potential in hPSCs.
Motosugi N, Okada C, Sugiyama A, et al. · Cell Rep · 2021Research Support, Non-U.S. Gov't
- Model-Based 3-D X-Ray Induced Acoustic Computerized Tomography.
Pandey PK, Wang S, Sun L, et al. · IEEE Trans Radiat Plasma Med Sci · 2023
- XACT-seq: A photocrosslinking-based technique for detection of the RNA polymerase active-center position relative to DNA in Escherichia coli.
Pukhrambam C, Vvedenskaya IO, Nickels BE · STAR Protoc · 2021Research Support, N.I.H., Extramural
- XACT Noncoding RNA Competes with XIST in the Control of X Chromosome Activity during Human Early Development.
Vallot C, Patrat C, Collier AJ, et al. · Cell Stem Cell · 2017Research Support, Non-U.S. Gov't
- X-ray-induced acoustic computed tomography (XACT) imaging with single-shot nanosecond x-ray.
Wang S, Ivanov V, Pandey PK, et al. · Appl Phys Lett · 2021
- Model-Based X-Ray-Induced Acoustic Computed Tomography.
Pandey PK, Wang S, Aggrawal HO, et al. · IEEE Trans Ultrason Ferroelectr Freq Control · 2021Research Support, N.I.H., Extramural
- X chromosome inactivation in human development.
Patrat C, Ouimette JF, Rougeulle C · Development · 2020Research Support, Non-U.S. Gov't, Review
Other devices of this type
Also filed under product code NIM.
- ENROUTE Transcarotid Stent SystemBoston Scientific Corporation · PMA 2023
- Rx Acculink Carotid Stent SystemAbbott Vascular · PMA 2016
- Carotid Wallstent Monorail EndoprosthesisBoston Scientific Corp · PMA 2024
- Acculink Carotid Stent System and Rx Acculink Carotid Stent SystemAbbott Vascular · PMA 2017
- Roadsaver/CASPER Carotid Stent DeviceMicroVention, Inc. · PMA 2025
- Cartoid Wallstent Monorail EndoprosthesisBoston Scientific Corp · PMA 2012
- Protege Gps & Protege Rx Carotid Stent SystemsMedtronic Vascular, Inc. · PMA 2011
- Cordis Precise Nitinol StentCordis US Corporation · PMA 2008
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.